Antibodies aimed at the protein tau, which accumulates during the later stages of Alzheimer’s disease (AD), do not need to engage immune cells to clear the protein, and they were less toxic to neurons in cell culture experiments than antibodies that did bind to immune cells as well as tau.more »
DUBLIN – Glaxosmithkline plc is adding a second cytokine-targeting antibody to its respiratory disease portfolio by in-licensing Johnson & Johnson's CNTO 7160, a phase I antibody that targets the interleukin-33 (IL-33) receptor.
Comprehensive health assessment of a group of 13 cloned sheep, including the "Nottingham Dollies," four sheep that were created from the same cell line as Dolly the Sheep, has shown that, as a group, the animals were no more prone to health problems than naturally conceived sheep of the same age.
- Newly launched Carb-x partnership links U.S., U.K. efforts to boost AMR pipeline
- China’s Fosun moves into India with offer to acquire Gland for $1.3B
- Biomarin serves up ‘bloody good data’ on BMN 270 hemophilia A gene therapy
- Progress, setbacks in understanding tau
- FDA OKs lixisenatide for type 2 diabetics, sets stage for Lantus combo
- CRISPR heading to the clinic: First gene-editing trial set to start in China
- No buyout as Sciclone closes strategic review; keeps Nasdaq listing
- Another step forward: India releases updated biosimilar guidelines
- Anti-parasitic drug shows potential for treating breast cancer
- Nascent deal brings preclinical-stage cancer dru...
Over 45 years have elapsed since President Richard Nixon, in his State of the Union address on Jan, 22, 1971, asked for an appropriation of an extra $100 million to launch an intensive campaign to find a cure for cancer. "The time has come in America when the same kind of concentrated effort that split the atom and took man to the moon should be turned toward conquering this dread disease. Let us make a total national commitment to achieve this goal."
A team from the University of Tuebingen has identified the first bactericidal compound produced by a member of the human microbiome.
- Proteins acting as RNA-binders may point to new heart disease cure »
- Anti-parasitic drug shows potential for treating breast cancer »
- Potential new target for candidiasis identified »
- Cancer immunology drugs may return to their roots »
- Novel treatment for tumors with DNA repair deficiencies »
- Getting more mileage out of kinder, gentler CAR T cells »
- Checkpoint blockade success will take two, or three, to tango »
- Mobilizing innate, adaptive immune response in cancer »
- Cancer stem cell vaccine shown optimal in adjuvant setting »
- Ethically speaking: What’s the right thing to do?July 29, 2016 | 7:41 PM | Posted by: Lynn Yoffee
- For the birds, or the BlackBerries: Titles to intrigue and entertain in BioWorld’s 10th Annual Summer Reading ListJune 01, 2016 | 7:52 PM | Posted by: Marie Powers
- An end to Charlotte’s web?May 10, 2016 | 9:09 PM | Posted by: Mari Serebrov
- Building a wall to keep companies inApril 05, 2016 | 9:10 PM | Posted by: Mari Serebrov
- Ignoring the science for a bigger box of crayonsMarch 08, 2016 | 9:58 PM | Posted by: Mari Serebrov
Partners in Focus
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter